Best Practices in Advanced Glucose Monitoring

Slides:

Advertisements

Similar presentations

Do you require any assistance? Do you experience any symptoms? Calit2 Summer Research Program Minimize Hypoglycemic Episodes Utilizing Remote Assistance.

Advertisements

1 Type 1 Diabetes Mellitus Treatment. 2 Goals of T1DM Management Utilize intensive therapy aimed at near-normal BG and A1C levels Prevent diabetic ketoacidosis.

Type 2 Diabetes Glucose Management Goals 1. AACE Comprehensive Diabetes Care: Glucose Goals ParameterTreatment Goal for Nonpregnant Adults A1C (%)Individualize.

Canadian Diabetes Association Clinical Practice Guidelines Monitoring for Glycemic Control Chapter 9 Lori Berard, Ian Blumer, Robyn Houlden, David Miller,

A Day in the Life of a Type 2 Diabetic

Use of The FreeStyle Navigator TM Continuous Glucose Monitoring System in Children on Glargine- based Multiple Daily Injection Therapy Stuart Weinzimer.

1 Part 2 Routinely Identifying Postprandial Hyperglycemia - Challenges & Tools An Educational Service from G LYCO M ARK G LYCO M ARK is a registered trademark.

An Educational Service from GlycoMark

Pattern Recognition Ver D/sv/ What Is Pattern Management ? A systematic approach to making effective use of SMBG data. – Establishing pre-

Risk Factors Associated With Severe Hypoglycemia in Older Adults With Type 1 Diabetes Featured Article: Ruth S. Weinstock, Stephanie N. DuBose, Richard.

Introduction Subcutaneous insulin absorption is not reproducible and insulin entry directly into the circulation is not linked to glucose sensing Basal.

Copyright © 2015 by the American Osteopathic Association.

Dr Adhya Mehta Department of Medicine

Type 1 Diabetes: Meters, Pumps, and Transitions to Adulthood

Diabetes and Risk of CV Outcomes

Lifestyle and Professional CGM

Patient Case 1 Peggy Peggy Interactive Case Question.

Special Consideration in Insulin Therapy

Faster-Acting Insulins

Statin Selection Aimed to Reduce New-Onset DM Risk:

Program Goals. Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding.

Using the AGP to Standardize Glucose Reporting

New Patient-Friendly Options for Managing Insulin Dosing

Value of construct 1. Fits with Harry Keen’s construct

What Comes Second?.

SGLT2 Inhibitors in Phase 3 Trials

Clinical Advances in Type 2 Diabetes and Cardiovascular Risk

Hemoglobin A1c Targets for Glycemic Controls

↑- likely due to hypoglycemia and weight gain

Panelists. Unique Perspectives on the Cost Burden of Diabetes in the United States.

Updates to Managing Diabetes in the Long-Term Care Setting

Goals. Achieving HbA1c Goals: Applying Guidelines to Intensify Therapy in Patients With Diabetes.

Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population

Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?

Vicious Circle(s) of Hyperinsulinemia- Result in Weight Gain and Hypoglycemia Undue Or bolus Hypoglycemia Symptomatic or not!

Need to Know! Screening and Diagnosis of Kidney Disease in Diabetes

Faster-Acting Insulins

A: Percentage of type 1 diabetic and type 2 diabetic patients with asymptomatic hypoglycemias detected by the CGMS. B: Daily distribution of asymptomatic.

Integrated Diabetes Care: How Can We Make the Best Use of New Technology?

Growing Diabetes Pandemic Worldwide

A Journal Club on Lipid Management:

Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

The Research Question Does self monitoring of blood glucose (SMBG) in patients with non-insulin treated type 2 diabetes improve glycemia or quality of.

Simplifying Insulin Delivery for Better Patient Outcomes in T2D

Learning Objectives Metabolic Abnormalities Associated With T2D.

The Primary Care Guide to New CGM Devices and the AGP

Novel Approaches to T1D Management

Glucose Monitoring: An Evolving Landscape

Fig. 1. Glycemic variability in three hypothetical patients who have the same mean blood glucose concentration. Patient B has relatively small variations.

Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population

T2DM Management.

Better Diabetes Control With Novel Basal Insulins

Modern Advances in Glucose Monitoring

Younger Patients With Type 1 Diabetes: Can We Optimize Their Insulin Therapy?

Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.

Pharmacotherapy for Diabetic Coronary Disease:

Dual SGLT1/SGLT2 Inhibition in T1D

Advancements in Glucose Monitoring

Key Insulin Side Effects*

Hypoglycemia: The Most Common Barrier to Effective Diabetes Management

Diabetes Update: 2018 Standards of Care

Hypoglycemia Is BAD.

NP and PA Expert Exchange:

Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA

Statins and Glucose Metabolism: An Endocrinology Perspective

Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.

Statin Selection in Patients With Pre-Diabetes: Case Considerations

New Advances in Hybrid Closed-Loop Control of Insulin Therapy

Fresh perspectives ON BASAL Insulins in diabetes care

Benchmarking scatterplot for non-ICU units.

Presentation transcript:

Best Practices in Advanced Glucose Monitoring

The Scope of the Problem

The AGP

The Ongoing Need

A Closer Look: the AGP

Utilizing AGP in Patients With T1D and T2D

Best Practices in Advanced Glucose Monitoring

Challenges in Diabetes Management Comorbidities in Aging and Diabetes

What Should Be the Glycemic Goal in Older Adults?

Frequent Hypoglycemic Episodes Detected by CGM Age ≥ 69 y; HbA1c > 8%; N = 40

Lack of Association Between HbA1c Levels and Hypoglycemia Risk

HbA1c Level Does Not Reflect Glucose Excursions, but CGM With the AGP Does

Best Practices in Advanced Glucose Monitoring

Limitations of SMBG in Patients With T1D

Professional vs Personal CGM

FGM With FSLP in Patients With T1D

Where to Start?

Ouch!

Getting Granular

Best Practices in Advanced Glucose Monitoring

58-Year-Old Man With T2D for 10 Years

2-Week Summary of Patient Ambulatory BG Readings

Talking to Your Patient

Closing Comments

Abbreviations